EpiCept Initiates Post-Approval Clinical Study With Ceplene
EpiCept has initiated post-approval clinical study with Ceplene (histamine dihydrochloride), following Ethics Committee and Competent Authority approvals in Sweden, Belgium, and France. The company said that the study
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.